The announced effectiveness of IFN-α in the treatment of patients with severe COVID-19 has been ambiguous: some work indicated a lack of positive effects [21,22], while at the same time, the effectiveness of such a treatment was confirmed in cohort studies [23,24] as well as clinical trials [25,26]. Here, IFNA17 is linked to COVID-19.